Biotechnology FundRYOAX
Type
Mutual fund
Peer group
US equity: Healthcare
Net assets
$135.1M
Expense ratio
—
1-year return
+34.9%
3 years, a year
+12.5%
5 years, a year
+4.5%
Holdings
75
Top 10 holdings.
| Holding | % of fund |
|---|---|
| ABBV AbbVie Inc. | 7.40% |
| AMGN Amgen Inc. | 5.23% |
| GILD Gilead Sciences Inc. | 4.96% |
| VRTX Vertex Pharmaceuticals Incorporated | 4.01% |
| REGN Regeneron Pharmaceuticals, Inc. | 3.56% |
| ALNY Alnylam Pharmaceuticals Inc. | 2.60% |
| INSM Insmed Inc | 2.46% |
| ONC Beone Medicines Ltd | 2.29% |
| NTRA Natera Inc | 2.09% |
| UTHR United Therapeutics Corporation | 2.07% |
More on RYOAX.
- RYOAX overview
- RYOAX holdings
- RYOAX risk
- RYOAX costs
- RYOAX money in and out
- RYOAX share classes
- Compare RYOAX with other funds
Returns after fees, from the fund's SEC filings up to Mar 2026. Past returns are not a promise. Not financial advice.